Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04895579 | Lung Cancer With Copanlisib and Durvalumab(LCD) | completed | Phase 1 | 11 | Zhonglin HaoOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT02812667 | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Lyudmila Bazhenova, M.D.OTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04647487 | A Study of LY3484356 in Women With Breast Cancer Before Having Surgery(EMBER-2) | completed | Phase 1 | 87 | Eli Lilly and CompanyINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT01489865 | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 64 | Georgetown UniversityOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT01526096 | Stem Cell Transplantation for Patients With Multiple Myeloma | completed | Phase 1 | 30 | University of ChicagoOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT05847686 | Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | completed | Phase 1 / Phase 2 | 55 | University of WashingtonOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT02199665 | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma(SINE) | completed | Phase 1 | 52 | University of ChicagoOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT01397708 | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | completed | Phase 1 / Phase 2 | 26 | Alaunos TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03010176 | Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | completed | Phase 1 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Oct 29, 2025 | clinicaltrials |
| NCT03192462 | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer(TACTOPS) | completed | Phase 1 / Phase 2 | 37 | Baylor College of MedicineOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03480646 | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 175 | Constellation PharmaceuticalsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Oct 28, 2025 | clinicaltrials |
| NCT02599454 | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 20 | Megan Daly, MDOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT04824443 | Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19 | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05091346 | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 89 | Eisai Inc.INDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 320 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 22, 2025 | clinicaltrials |
| NCT02879643 | Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy | completed | Phase 1 | 29 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 22, 2025 | clinicaltrials |
| NCT04826393 | ASP8374 + Cemiplimab in Recurrent Glioma | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03602235 | High Dose Ascorbic Acid for Plasma Cell Disorders | completed | Phase 1 | 6 | Christopher StrouseOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04660812 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.(ARC-9) | completed | Phase 1 / Phase 2 | 227 | Arcus Biosciences, Inc.INDUSTRY | 6 | Oct 20, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
| NCT04601831 | 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL | completed | Phase 1 / Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | completed | Phase 1 | 135 | Prelude TherapeuticsINDUSTRY | 5 | Oct 16, 2025 | clinicaltrials |
| NCT02512926 | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children(POE14-01) | completed | Phase 1 | 4 | Stanford UniversityOTHER | 2 | Oct 15, 2025 | clinicaltrials |
| NCT05025085 | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | completed | Phase 1 | 25 | Agenus Inc.INDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03515512 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06644170 | A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | completed | Phase 1 | 15 | University of WashingtonOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies(ELM-1) | completed | Phase 1 | 200 | Regeneron PharmaceuticalsINDUSTRY | 5 | Oct 10, 2025 | clinicaltrials |
| NCT03404960 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy(Parpvax) | completed | Phase 1 / Phase 2 | 104 | University of PennsylvaniaOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04540796 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 147 | Janssen Research & Development, LLCINDUSTRY | 8 | Oct 10, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT00673010 | Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma | completed | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 332 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 9, 2025 | clinicaltrials |
| NCT04023110 | Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab(CCTGuide Pilot) | completed | Phase 1 | 68 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT04169711 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | completed | Phase 1 | 26 | Arrowhead PharmaceuticalsINDUSTRY | 1 | Oct 9, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 18, 2025source: clinicaltrials